Notification
No new Notification messages
Swiggy IPO is Open!
Apply for the Swiggy IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Diwali Offer: MTF at just 9.99%
Iss Diwali, Investments Ko Karo 4X with our Trade Now, Pay Later (MTF) feature
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
glenmark pharmaceuticals stock

GLENMARK PHARMACEUTICALS Share Price

1742.1 16.94 (0.98%)
Nov 06 2024 10:16 AM Pharmaceuticals NSE: GLENMARK

GLENMARK PHARMACEUTICALS Share Price Update

As of the latest trading session, GLENMARK PHARMACEUTICALS share price is currently at 1742.1, which is up by 16.94 from its previous closing. Today, the stock has fluctuated between 1721.50 and 1755.85. Over the past year, GLENMARK PHARMACEUTICALS has achieved a return of 128.36 %. In the last month alone, the return has been 2.98 %. Read More...

GLENMARK PHARMACEUTICALS Performance

Day Range

Low1721.50 High1755.85
1725.05

52 Week Range

Low 722.10 High 1830.95
1725.05

GLENMARK PHARMACEUTICALS Share Price

7406

532296

GLENMARK

img img img img
No Data Available

Open Price

1725.05

Prev. Close

1725.15

Volume (Shares)

1479.00

Total traded value

25.51

Upper Circuit

1897.65

Lower Circuit

1552.65

Note: The current prices & values are delayed, Login to your account for live updates.

GLENMARK PHARMACEUTICALS Fundamentals


(Standalone)

Market Cap (Cr) 49160.00
PE Ratio (TTM) 9.10
Book Value / Share 814.01
Beta 0.82
ROE 6.98%
EPS (TTM) 57.32
Dividend Yield 0.14%
Net Profit Qtr (Cr) 453.73

GLENMARK PHARMACEUTICALS Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars JUN 2024 (Values in Cr)
Revenue 2296.88
Operating Expense 1766.87
Net Profit 453.73
Net Profit Margin (%) 19.75
Earnings Per Share (EPS) 16.08
EBITDA 686.75
Effective Tax Rate (%) 26.61
Particulars MAR 2024 (Values in Cr)
Revenue 2077.13
Operating Expense 1786.57
Net Profit 4613.70
Net Profit Margin (%) 222.11
Earnings Per Share (EPS) 163.50
EBITDA 6430.64
Effective Tax Rate (%) 26.70
Particulars DEC 2023 (Values in Cr)
Revenue 1304.16
Operating Expense 1674.12
Net Profit -20.41
Net Profit Margin (%) -1.56
Earnings Per Share (EPS) -0.72
EBITDA 49.25
Effective Tax Rate (%) 72.96
Particulars SEP 2023 (Values in Cr)
Revenue 2170.40
Operating Expense 1897.96
Net Profit 302.35
Net Profit Margin (%) 13.93
Earnings Per Share (EPS) 10.72
EBITDA 497.41
Effective Tax Rate (%) 22.34
Particulars JUN 2023 (Values in Cr)
Revenue 2098.06
Operating Expense 1770.07
Net Profit 271.66
Net Profit Margin (%) 12.94
Earnings Per Share (EPS) 9.63
EBITDA 502.72
Effective Tax Rate (%) 30.70
Particulars MAR 2024 (Values in Cr)
Revenue 7649.76
Operating Expense 7128.73
Net Profit 5167.29
Net Profit Margin (%) 67.54
Earnings Per Share (EPS) 183.13
EBITDA 7480.01
Effective Tax Rate (%) 26.18
Particulars MAR 2023 (Values in Cr)
Revenue 8019.67
Operating Expense 7138.86
Net Profit 1208.77
Net Profit Margin (%) 15.07
Earnings Per Share (EPS) 42.84
EBITDA 1962.84
Effective Tax Rate (%) 23.10
Particulars MAR 2022 (Values in Cr)
Revenue 8017.38
Operating Expense 6849.10
Net Profit 1997.79
Net Profit Margin (%) 24.91
Earnings Per Share (EPS) 70.80
EBITDA 2733.18
Effective Tax Rate (%) 14.53
Particulars MAR 2021 (Values in Cr)
Revenue 7450.91
Operating Expense 6094.30
Net Profit 1649.45
Net Profit Margin (%) 22.13
Earnings Per Share (EPS) 58.46
EBITDA 2360.48
Effective Tax Rate (%) 15.14
Particulars MAR 2020 (Values in Cr)
Revenue 6491.20
Operating Expense 5803.33
Net Profit 1354.55
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 48.00
EBITDA 1929.57
Effective Tax Rate (%) 11.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 278.11
ROE % -50.87
ROCE % 12.05
Total Debt to Total Equity 0.34
EBITDA Margin 17.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 335.75
ROE % 7.43
ROCE % 9.75
Total Debt to Total Equity 0.46
EBITDA Margin 16.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 322.03
ROE % 14.36
ROCE % 15.77
Total Debt to Total Equity 0.55
EBITDA Margin 20.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 250.37
ROE % 14.77
ROCE % 14.70
Total Debt to Total Equity 0.75
EBITDA Margin 19.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.14
ROE % 13.29
ROCE % 13.70
Total Debt to Total Equity 0.80
EBITDA Margin 17.77
Particulars MAR 2024 (Values in Cr)
Book Value / Share 814.01
ROE % 6.98
ROCE % 9.75
Total Debt to Total Equity 0.10
EBITDA Margin 30.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 633.57
ROE % 9.12
ROCE % 10.79
Total Debt to Total Equity 0.20
EBITDA Margin 29.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 593.21
ROE % 10.42
ROCE % 10.93
Total Debt to Total Equity 0.24
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 524.84
ROE % 11.77
ROCE % 12.39
Total Debt to Total Equity 0.26
EBITDA Margin 31.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 468.73
ROE % 10.76
ROCE % 11.13
Total Debt to Total Equity 0.27
EBITDA Margin 28.75
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1659.45
Total Assets 14358.62
Total Liabilities 14358.62
Total Equity 7847.54
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) -10.45
Return on Capital (%) -16.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1160.29
Total Assets 19371.67
Total Liabilities 19371.67
Total Equity 9839.25
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 1.53
Return on Capital (%) 2.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1411.51
Total Assets 17083.28
Total Liabilities 17083.28
Total Equity 9438.12
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 5.51
Return on Capital (%) 7.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1139.15
Total Assets 15603.57
Total Liabilities 15603.57
Total Equity 7064.27
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 6.21
Return on Capital (%) 8.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1111.24
Total Assets 14684.80
Total Liabilities 14684.80
Total Equity 6070.11
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 5.28
Return on Capital (%) 7.35
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 129.15
Total Assets 27414.39
Total Liabilities 27414.39
Total Equity 22970.62
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) 18.84
Return on Capital (%) 21.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.79
Total Assets 24585.92
Total Liabilities 24585.92
Total Equity 17877.46
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 4.91
Return on Capital (%) 5.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.63
Total Assets 22914.48
Total Liabilities 22914.48
Total Equity 16738.58
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 8.71
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.78
Total Assets 20617.52
Total Liabilities 20617.52
Total Equity 14809.50
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 8.00
Return on Capital (%) 8.95
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 88.25
Total Assets 18951.59
Total Liabilities 18951.59
Total Equity 13226.26
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 7.14
Return on Capital (%) 8.06
Particulars MAR 2024 (Values in Cr)
Net Income 569.18
Cash from Operations 782.04
Cash from Investing 4560.89
Cash from Financing -3906.12
Net change in Cash 389.32
Free Cash Flow 1680.42
Particulars MAR 2023 (Values in Cr)
Net Income 868.45
Cash from Operations 1265.93
Cash from Investing -528.49
Cash from Financing -77.45
Net change in Cash 19.44
Free Cash Flow 1873.69
Particulars MAR 2022 (Values in Cr)
Net Income 1441.24
Cash from Operations 1667.09
Cash from Investing -333.28
Cash from Financing -520.49
Net change in Cash 254.88
Free Cash Flow 2457.21
Particulars MAR 2021 (Values in Cr)
Net Income 1382.47
Cash from Operations 1641.45
Cash from Investing -675.23
Cash from Financing -441.77
Net change in Cash 14.19
Free Cash Flow 2416.21
Particulars MAR 2020 (Values in Cr)
Net Income 1096.07
Cash from Operations 1859.36
Cash from Investing -783.51
Cash from Financing -444.66
Net change in Cash 173.99
Free Cash Flow 2791.78
Particulars MAR 2024 (Values in Cr)
Net Income 7000.74
Cash from Operations 375.64
Cash from Investing 3197.19
Cash from Financing -2666.44
Net change in Cash 35.29
Free Cash Flow 570.76
Particulars MAR 2023 (Values in Cr)
Net Income 1571.87
Cash from Operations 1890.48
Cash from Investing -431.46
Cash from Financing -978.49
Net change in Cash 64.09
Free Cash Flow 2080.10
Particulars MAR 2022 (Values in Cr)
Net Income 2337.44
Cash from Operations 1606.78
Cash from Investing -896.92
Cash from Financing -305.12
Net change in Cash 14.02
Free Cash Flow 1770.13
Particulars MAR 2021 (Values in Cr)
Net Income 1943.75
Cash from Operations 1579.25
Cash from Investing -1235.23
Cash from Financing -80.79
Net change in Cash -72.60
Free Cash Flow 1790.72
Particulars MAR 2020 (Values in Cr)
Net Income 1534.64
Cash from Operations 1918.46
Cash from Investing -1607.38
Cash from Financing -139.41
Net change in Cash -167.68
Free Cash Flow 2037.66
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 56.52 36.70 3.15 433.13 35.27 / 77.70
BLISS GVS PHARMA LTD 123.50 15.46 1.28 1300.48 92.25 / 148.95
CIPLA LTD 1601.25 28.01 4.55 129316.22 1165.10 / 1702.00
FERMENTA BIOTECH LIMITED 321.70 0.00 3.27 946.79 144.45 / 332.50
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 56.52 85.64 10.74 433.13 35.27 / 77.70
AMRUTAJAN HEALTH LTD 744.45 50.54 7.46 2152.25 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 7478.00 142.71 26.25 18695.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 123.50 16.08 1.26 1300.48 92.25 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 1700.80
  • 26 Days 1705.40
  • 10 Days 1694.00
  • 50 Days 1706.40
  • 12 Days 1700.80
  • 100 Days 1577.20
  • 20 Days 1712.00
  • 200 Days 961.50
1710.52
PIVOT
First Resistance 1752.03
Second Resistance 1778.92
Third Resistance 1820.43
First Support 1683.63
Second Support 1642.12
Third Support 1615.23
RSI 40.23
MACD -4.61
Commodity Channel Index (CCI) -22.83
ADX 8.06
Williams % R -39.96

Over 1 Month

down

2.98

Over 3 Months

down

21.67

Over 6 Months

down

65.77

Over 1 Year

down

128.36

Over 3 Years

down

48.51

Over 5 Years

down

40.32

GLENMARK PHARMACEUTICALS Future

Future: Price

28 Nov
1749.45
26 Dec
1762.05
25 May
0 100 200 300 400 500 600

Discount/Premium

28 Nov
12.50
26 Dec
25.10
25 May
0 1 2 3 4 5 6 7

Active Calls

1800.0
344
1740.0
244
1900.0
194
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

1700.0
170
1600.0
122
1500.0
51
25 Jul
0 500 1000 1500 2000 2500

GLENMARK PHARMACEUTICALS Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
0.0
Promoter Holdings
0.0
FII
0.0
DII
0.0
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Saldanha Family Trust Shareholding of Promoter and Promoter Group 1.28241936E8 45.45
Hdfc Mutual Fund-hdfc Arbitrage Fund Public Shareholding 9662757.0 3.42
Government Pension Fund Global Public Shareholding 9181327.0 3.25
Smallcap World Fund, Inc Public Shareholding 8755888.0 3.1
Mirae Asset Elss Tax Saver Fund Public Shareholding 7896195.0 2.8
Ashish Dhawan Public Shareholding 7200000.0 2.55
Ellipsis Partners Llc Public Shareholding 3699943.0 1.31
Aditya Birla Sun Life Trustee Private Limited A/c Public Shareholding 3247446.0 1.15
Invesco India Midcap Fund Public Shareholding 3015552.0 1.07
Blanche Elizabeth Saldanha Shareholding of Promoter and Promoter Group 1114327.0 0.39
Glenn Mario Saldanha Shareholding of Promoter and Promoter Group 992939.0 0.35
Cherylann Maria Pinto Shareholding of Promoter and Promoter Group 758485.0 0.27
Robin Joseph Pinto Shareholding of Promoter and Promoter Group 497500.0 0.18
Neha Saldanha Shareholding of Promoter and Promoter Group 26000.0 0.01

GLENMARK PHARMACEUTICALS

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-09-18 2.5 Final 2023-09-19 Equity shares 2022-09-12 2.5 Final 2022-09-14 Equity shares 2021-09-08 2.5 Final 2021-09-10 Equity shares 2020-09-17 2.5 Final 2020-09-19 Equity shares 2019-09-19 2.0 Final 2019-09-21 Equity shares 2018-09-19 2.0 Final 2018-09-22 Equity shares 2017-09-20 2.0 Final 2017-09-22 Equity shares 2016-08-03 2.0 Final 2016-08-05 Equity shares 2015-09-10 2.0 Final 2015-09-14 Equity shares 2014-07-10 2.0 Final 2014-07-14 Equity shares 2013-07-18 2.0 Final 2013-07-22 Equity shares 2012-07-19 2.0 Final 2012-07-23 Equity shares 2011-07-28 0.4 Final 2011-08-01 Equity shares 2010-09-16 0.4 Final 2010-09-20 Equity shares 2009-09-10 0.4 Final 2009-09-14 Equity shares 2007-11-07 1.4 Interim 2007-11-08 Equity shares 2007-01-04 0.8 Interim 2007-01-05 Equity shares 2005-04-27 0.0 Interim 2005-05-02 Equity shares
Ex-Date Ex-Bonus Ratio
2005-03-08 2005-03-04 1:1
Ex-Date Old FV NEW FV Record Date
2007-09-10 2.0 1.0 2007-09-17 2003-10-23 10.0 2.0 2003-10-31

Learn More About Stocks

About GLENMARK PHARMACEUTICALS

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by GLENMARK PHARMACEUTICALS

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

The share price of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1742.1 and for BSE is ₹ 1742.45.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE is ₹ 4,91,60.00 Cr. and for BSE is ₹ 4,91,69.88 Cr. as of now.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1830.95 and ₹ 722.10 and for BSE is ₹ 1830.05 and ₹ 702.05.

How to Buy Glenmark Pharmaceuticals Ltd share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Glenmark Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 128.36%.

What is the Current Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

Glenmark Pharmaceuticals Ltd share price is for NSE ₹ 1742.1 & for BSE ₹ 1742.45 as on Nov 06 2024 10:16 AM.

What is the Market Cap of Glenmark Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE ₹ 4,91,60.00 & for BSE ₹ 4,91,69.88 as on Nov 06 2024 10:16 AM.

What is the P/E Ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Nov 06 2024 10:16 AM the price-to-earnings (PE) ratio for Glenmark Pharmaceuticals Ltd share is 9.10.

What is the PB ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Nov 06 2024 10:16 AM, the price-to-book (PB) ratio for Glenmark Pharmaceuticals Ltd share is 814.01.

How to Buy Glenmark Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glenmark Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glenmark Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glenmark Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader